Royalty Pharma (RPRX) Other Non-Current Assets (2019 - 2026)

Royalty Pharma has disclosed Other Non-Current Assets across 8 years of filings, most recently posting $76.8 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $76.8 million, up 109.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.8 million (up 109.36% YoY), and the FY2025 annual result was $79.3 million, up 136.46% from the prior year.
• Other Non-Current Assets came in at $76.8 million for Q1 2026 at Royalty Pharma, down from $79.3 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $86.6 million in Q3 2025 to a low of $3.9 million in Q1 2022.
• The 5-year median for Other Non-Current Assets is $30.6 million (2022), against an average of $38.5 million.
• Across the five-year window, Other Non-Current Assets slumped 83.99% in 2024 and surged 717.89% in 2025, its largest moves.
• Royalty Pharma's Other Non-Current Assets stood at $29.6 million in 2022, then slumped by 77.99% to $6.5 million in 2023, then jumped by 414.17% to $33.5 million in 2024, then soared by 136.46% to $79.3 million in 2025, then fell by 3.08% to $76.8 million in 2026.
• The last three Other Non-Current Assets figures came in at $76.8 million (Q1 2026), $79.3 million (Q4 2025), and $86.6 million (Q3 2025), per Business Quant data.